Nirogacestat and Famotidine not checked

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“oral dose of 150 mg nirogacestat \& oral dose of 40 mg famotidine”In the company’s words, NCT07171619 on ClinicalTrials.gov
Main trialPhase 1
“This study will evaluate the effects of the H2 blocker famotidine or the PPI rabeprazole on the PK of nirogacestat in healthy male participants”In the company’s words, NCT07171619 on ClinicalTrials.gov

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Completed 10 Nov 2025 Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Nirogacestat and Famotidine

Following is part of Solo: you see every change to Nirogacestat and Famotidine the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in